TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This ‘Purecap’ technique ...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has launched its newest ...
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This 'Purecap' technique ...
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This 'Purecap' technique ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...
A research group used a unique 'PureCap' method to produce high purity mRNA vaccines with improved synthesis of proteins that stimulate the immune system and low inflammatory side effects. A research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results